On Tuesday, Seattle Genetics, Inc. (NASDAQ:SGEN)’s shares inclined 4.91% to $45.52.
Seattle Genetics, Inc. (SGEN) declared several ADCETRIS (brentuximab vedotin) data presentations in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 29 to June 2, 2015, in Chicago, IL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL) and several other types of non-Hodgkin lymphoma.
Data were stated from a multivariate analysis of the effects of demographics, baseline disease characteristics and other risk factors on progression-free survival (PFS) from the phase 3 AETHERA clinical trial. After adjusting for several clinical factors in a multivariate regression analysis, consolidation treatment with ADCETRIS was significantly associated with improved PFS contrast with placebo (hazard ratio of 0.44) and was more important, or as important, as all evaluated clinical factors. Results show comprising PFS benefit of ADCETRIS consolidation therapy, regardless of the clinical factors, further supporting ADCETRIS use as consolidation in HL patients following autoloagous stem cell transplant (ASCT).
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially accessible in about 50 countries, counting the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in partnership with Takeda Pharmaceutical Company Limited.
Edison International (NYSE:EIX)’s shares dropped -2.04% to $59.54.
Edison International (EIX) is furnishing this Form 8-K/A for the sole purpose of providing corrections to the presentation used in connection with the conference, which is furnished with this report on amended Exhibit 99.1. No other changes to the Original 8-K have been made. Exhibit 99.1 is amended by correcting the Southern California Edison Company (“SCE”) Historical Rate Base, Rate Base Forecast, and Capital Expenditures Forecast slides of the presentation to add the correct dollar amounts at top of certain columns. SCE’s historical rate base, rate base forecast, and capital expenditures forecast are not otherwise being changed or amended. The updated version of Exhibit 99.1 is attached hereto and supersedes Exhibit 99.1 to the Original Form 8-K in its entirety.
The information furnished in this Item 7.01 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933.
Edison International, through its auxiliaries, generates and supplies electricity. The company generates electricity through hydroelectric, diesel, natural gas, nuclear, and photovoltaic sources.
At the end of Tuesday’s trade, T. Rowe Price Group Inc (NASDAQ:TROW)‘s shares dipped -0.66% to $80.28.
- Rowe Price Group Inc (TROW) declared that it closed its Health Sciences Fund and similar portfolios for institutional clients at 4 p.m. ET recently. The decision to close the fund was made to maintain the integrity of the fund’s investment strategy and to protect the interests of existing shareholders. While the fund is closed to new investors, it will continue to accept additional investments from existing shareholders and from participants in an employer-sponsored retirement plan for which the fund serves as an investment option. New IRAs may also be opened through a direct rollover from an employer-sponsored retirement plan.
- Rowe Price Health Sciences Fund, which launched on December 29, 1995, seeks long-term capital appreciation from the stocks of companies involved in health care, medicine, and life sciences. It has been managed since February 15, 2013, by Taymour Tamaddon, who has been an investment professional at T. Rowe Price since 2004. The Health Sciences Fund received an Overall Morningstar RatingTM of five stars as of April 30, 2015.1 Its ticker symbol is PRHSX.
- Rowe Price Group, Inc. is a publicly owned asset administration holding company. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It invests in the public equity and fixed income markets across the globe. It also invests in alternative markets, counting currency markets. The firm employs fundamental and quantitative analysis with a bottom-up approach. It utilizes in-house and external research to make its investments.
McGraw Hill Financial Inc (NYSE:MHFI), ended its Tuesday’s trading session with -0.07% loss, and closed at $103.68.
McGraw Hill Financial Inc (MHFI) declared a noteworthy expansion of third-party credit research on its platform covering rated entities in ten countries across the Asia-Pacific region. As a result of a series of recently accomplished commercial agreements with local credit ratings agencies in East and Southeast Asia, subscribers to the S&P Capital IQ desktop can now access research, ratings, insights and recommendations from over 400 sell side, industry or specialty firms that cover more than 28,000 public and private companies throughout APAC. In addition, users can also obtain earnings estimates on 19,000 companies across the entire globe, counting many companies listed on Asia-Pacific stock exchanges.
McGraw Hill Financial, Inc. provides benchmarks and ratings, analytics, data, and research services for the capital, commodities, and commercial markets worldwide. It operates in four segments: Standard & Poor’s Ratings Services (S&P Ratings), S&P Capital IQ, S&P Dow Jones Indices (S&P DJ Indices), and Commodities & Commercial (C&C).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
